BioMedNewsBreaks – Artelo Biosciences Inc. (NASDAQ: ARTL) Appoints Senior Pharmaceutical Exec as New SVP, Chief Scientific Officer
Artelo Biosciences (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as senior vice president and chief scientific officer. Dr. Yates is an experienced senior pharmaceutical executive, having most recently served at AstraZeneca in significant roles across a number of functional areas including development and commercial strategy, medical affairs and business development. Notably, Dr. Yates has been extensively involved in the life-cycle management of key multi-billion-dollar products including CRESTOR(R), FORXIGA(R) and KEYTRUDA(R). “We are extremely pleased to announce the appointment of Andy as our chief scientific officer,” said Gregory Gorgas, Artelo’s president and chief executive officer. “As a valuable member of our scientific advisory board, he has made significant contributions to the growth of Artelo’s business including the clinical advancement of ART27.13 as a development candidate for cancer-related anorexia. Andy’s expertise in biopharmaceutical drug development combined with his entrepreneurial background is expected to be of significant value in supporting the clinical development of Artelo’s next-generation therapies in multiple areas, including anorexia, cancer, PTSD, pain, and inflammation.”
To view the full press release, visit https://ibn.fm/IzzLM
About Artelo Biosciences Inc.
Artelo Biosciences is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.ArteloBio.com.
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork